April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Optimizing Strategies for Bevacizumab Injections in ARMD: A Randomized Controlled Trial using 4, 6 and 8 Weekly Injections
Author Affiliations & Notes
  • Tetyana Lushchyk
    Oogziekenhuis Rotterdam, Rotterdam, The Netherlands
  • Sankha Amarakoon
    ROI, Rotterdam, The Netherlands
  • G.S. Baarsma
    Oogziekenhuis Rotterdam, Rotterdam, The Netherlands
  • L.I. Van den Born
    Oogziekenhuis Rotterdam, Rotterdam, The Netherlands
  • J.P. Martinez-Ciriano
    Oogziekenhuis Rotterdam, Rotterdam, The Netherlands
  • T Missotten
    Oogziekenhuis Rotterdam, Rotterdam, The Netherlands
  • Footnotes
    Commercial Relationships  Tetyana Lushchyk, None; Sankha Amarakoon, None; G.S. Baarsma, None; L.I. Van den Born, None; J.P. Martinez-Ciriano, None; T. Missotten, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 126. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tetyana Lushchyk, Sankha Amarakoon, G.S. Baarsma, L.I. Van den Born, J.P. Martinez-Ciriano, T Missotten; Optimizing Strategies for Bevacizumab Injections in ARMD: A Randomized Controlled Trial using 4, 6 and 8 Weekly Injections. Invest. Ophthalmol. Vis. Sci. 2011;52(14):126.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : This RCT studies the influence of frequency of administration of Bevacizumab injections on functional and anatomical outcomes in patients with ARMD.

Methods: : Ongoing prospective randomized controlled study. Patients (n=191) were allocated to one of three groups: 4 weekly (n=63), 6 weekly (n=63) or 8 weekly (n=65) injections with 1,25/0,05cc Bevacizumab for 1 year. Visual acuity, and changes in OCT were analysed.

Results: : At this point inclusion is completed, study in progress. 184 patients reached the 3 months, 175 the 6 months, 152 the 9 months and 134 the 12 months follow-up time point.At 3, 6, 9 and 12 months were no significant differences in gained ETDRS letters: p=0,31, p=0,68, p=0,56 and p=0,14 respectively. At 12 month ETDRS letters gained: 2,4±13,9 in the 4 weekly group, 1,4±11,5 in the 6 weekly and 5,9±8,7 in the 8 weekly injection group. No significant differences in reduction of OCT minimal foveal thickness were observed at 3, 6, 9 and even 12 moths time point: p=0,17, p=0,48, p=0,13 and p=0,46 respectively.At 12 months a reduction of 107,8±90 um, 83,0±86,6 um and 97,2±102um in the 4 weekly, 6 weekly and 8 weekly group respectively was found.

Conclusions: : In this ongoing study at 3, 6, 9 an 12 months follow-up point no superiority between 4-weekly, 6-weekly or 8-weekly Bevacizumab injections for ARMD could be observed.

Clinical Trial: : ROI, 2007-06

Keywords: retinal neovascularization • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×